Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Serenity Pharmaceuticals, Inc.
NCT05090722 · Nocturia
NCT05562388 · Obstructive Sleep Apnea, Nocturia, and more
NCT05300308 · Urogenital Cancer, Lower Limb Lymphedema, and more
NCT06754189 · Urinary Incontinence, Urinary Incontinence, Urge, and more
NCT06866834 · Women, Urinary Incontinence (UI), and more
Dr. Jolene Berg
San Antonio, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions